Payment overview · 2025
General Payments
$689.68
33 reported records · 10 companies
Healthcare provider profile · identity verified
Terry A Kurtts, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ELBERTA, AL · NPI 1144200510
Verified facts
What the public records show
CMS Open Payments records show Terry A Kurtts, M.D. received $689.68 in general payments during 2025 across 33 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $196.38 | 28.5% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $99.70 | 14.5% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $98.71 | 14.3% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $79.27 | 11.5% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $47.36 | 6.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $39.33 | 5.7% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $39.32 | 5.7% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $35.51 | 5.2% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $30.33 | 4.4% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.77 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $689.68 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $182.47 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $91.34 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $77.43 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $72.71 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $64.99 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $47.36 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $39.33 | 2 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $39.32 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $35.51 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $34.71 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $30.33 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.95 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $28.95 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.00 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $26.00 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.77 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 46 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 64 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 93 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
64 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 805 | 136 |
| Levothyroxine Sodium | Levothyroxine Sodium | 579 | 161 |
| Gabapentin | Gabapentin | 491 | 84 |
| Atorvastatin Calcium | Atorvastatin Calcium | 415 | 125 |
| Amlodipine Besylate | Amlodipine Besylate | 411 | 114 |
| Lisinopril | Lisinopril | 307 | 83 |
| Omeprazole | Omeprazole | 302 | 101 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 246 | 85 |
| Tramadol Hcl | Tramadol Hcl | 228 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 220 | 66 |
| Simvastatin | Simvastatin | 217 | 58 |
| Tizanidine Hcl | Tizanidine Hcl | 215 | 45 |
| Furosemide | Furosemide | 192 | 63 |
| Losartan Potassium | Losartan Potassium | 178 | 57 |
| Metformin Hcl | Metformin Hcl | 174 | 54 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 163 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 153 | 44 |
| Alprazolam | Alprazolam | 150 | 27 |
| Trazodone Hcl | Trazodone Hcl | 145 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 143 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 142 | 45 |
| Clonazepam | Clonazepam | 136 | 26 |
| Famotidine | Famotidine | 134 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 131 | 37 |
| Donepezil Hcl | Donepezil Hcl | 128 | 40 |
| Carvedilol | Carvedilol | 123 | 39 |
| Valsartan | Valsartan | 123 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 120 | 45 |
| Meloxicam | Meloxicam | 114 | 43 |
| Potassium Chloride | Potassium Chloride | 109 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 107 | 30 |
| Eliquis | Apixaban | 98 | 25 |
| Sertraline Hcl | Sertraline Hcl | 98 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 33 |
| Atenolol | Atenolol | 96 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 94 | 22 |
| Ozempic | Semaglutide | 93 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 28 |
| Prednisone | Prednisone | 92 | 43 |
| Allopurinol | Allopurinol | 88 | 28 |
| Lorazepam | Lorazepam | 87 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 22 |
| Methocarbamol | Methocarbamol | 80 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | 18 |
| Pregabalin | Pregabalin | 73 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 71 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 70 | 40 |
| Buspirone Hcl | Buspirone Hcl | 67 | 21 |
| Memantine Hcl | Memantine Hcl | 66 | 24 |
| Mupirocin | Mupirocin | 65 | 49 |
| Topiramate | Topiramate | 65 | 15 |
| Mounjaro | Tirzepatide | 64 | 11 |
| Temazepam | Temazepam | 64 | suppressed |
| Ondansetron Odt | Ondansetron | 62 | 23 |
| Promethazine Hcl | Promethazine Hcl | 62 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 60 | 19 |
| Metformin Hcl Er | Metformin Hcl | 60 | 20 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 59 | 11 |
| Montelukast Sodium | Montelukast Sodium | 59 | 20 |
| Amoxicillin | Amoxicillin | 58 | 31 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 43 |
| Oxycodone Hcl | Oxycodone Hcl | 57 | suppressed |
| Diazepam | Diazepam | 56 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 18 |
| Glimepiride | Glimepiride | 54 | 17 |
| Januvia | Sitagliptin Phosphate | 54 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 16 |
| Spironolactone | Spironolactone | 53 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 16 |
| Myrbetriq | Mirabegron | 50 | 12 |
| Azithromycin | Azithromycin | 49 | 34 |
| Celecoxib | Celecoxib | 48 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | 12 |
| Farxiga | Dapagliflozin Propanediol | 46 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 45 | 16 |
| Glipizide | Glipizide | 44 | 15 |
| Meclizine Hcl | Meclizine Hcl | 43 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 29 |
| Methylprednisolone | Methylprednisolone | 41 | 34 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 34 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Telmisartan | Telmisartan | 40 | 12 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 40 | suppressed |
| Ibuprofen | Ibuprofen | 39 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 31 |
| Sucralfate | Sucralfate | 39 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 38 | suppressed |
| Fluconazole | Fluconazole | 37 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 15 |
| Estradiol | Estradiol | 34 | 16 |
| Cephalexin | Cephalexin | 33 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Vascepa | Icosapent Ethyl | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Finasteride | Finasteride | 30 | 11 |
| Ketoconazole | Ketoconazole | 29 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Risperidone | Risperidone | 28 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 28 | suppressed |
| Acyclovir | Acyclovir | 27 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 20 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Nystatin | Nystatin | 19 | 14 |
| Fenofibrate | Fenofibrate,micronized | 18 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | suppressed |
| Erythromycin | Erythromycin Base | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Indapamide | Indapamide | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Hydroxyurea | Hydroxyurea | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Oxazepam | Oxazepam | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 11 | suppressed |
| Famciclovir | Famciclovir | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $689.68 · 33 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, CAPVAXIVE, DAYBUE, FARXIGA, GEMTESA, KISUNLA, MOUNJARO, Ozempic, QULIPTA, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Wegovy, YUPELRI | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error